Jaguar Animal Health Q2 2025 Earnings Report

Jaguar Animal Health EPS Results

• Actual EPS: N/A
• Consensus EPS: -$7.13
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Jaguar Animal Health Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $3.27 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Jaguar Animal Health Announcement Details

• Quarter: Q2 2025
• Date: 8/12/2025
• Time: Before Market Opens
• Conference Call Date: Tuesday, August 12, 2025
• Conference Call Time: 8:30AM ET

Jaguar Animal Health (NASDAQ:JAGX) is a commercial-stage animal health company dedicated to the development, licensing and commercialization of pharmaceutical products for companion animals, equine species and food-production animals. Founded in 2011 as a spin-out focused on veterinary medicine, Jaguar has built a product portfolio through strategic in-licensing, acquisitions and repurposing of human drugs for animal health indications.

The company’s lead product, Mytesi (crofelemer), received conditional approval from the U.S. Food and Drug Administration’s Center for Veterinary Medicine for the symptomatic relief of noninfectious diarrhea in dogs and cats. Leveraging the established human safety profile of crofelemer, Jaguar launched Mytesi in 2023 and has since been expanding its direct sales force and distribution network across major veterinary channels.

Beyond Mytesi, Jaguar’s pipeline includes clinical-stage and preclinical candidates targeting a range of high-value indications. These programs encompass an oral therapy for inflammatory bowel disease in canines, a novel antiepileptic treatment for companion animals and an equine oncology asset aimed at managing melanoma in horses. The company sources innovation through collaborations with academic institutions and biotechnology partners to accelerate development timelines.

Headquartered in Tampa, Florida, Jaguar Animal Health serves the U.S. market with plans to extend its reach into Canada and select European countries through strategic distribution agreements. The leadership team is led by Chief Executive Officer Eamonn Hobbs, whose two decades of pharmaceutical experience guide Jaguar’s commercial expansion, supported by Chief Operating Officer Daniel Marks and Chief Scientific Officer Dr. John Engelen.